Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation

SIMPLE SUMMARY: Radium-223 dichloride ([(223)Ra]RaCl(2); Ra-223) is an alpha-emitting radiopharmaceutical treatment for patients with metastatic castration resistant prostate cancer (mCRPC) with predominantly bone metastases. While responses to chemotherapeutic and antihormonal mCRPC treatments can...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Zande, Kim, Oyen, Wim J. G., Zwart, Wilbert, Bergman, Andries M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431634/
https://www.ncbi.nlm.nih.gov/pubmed/34503156
http://dx.doi.org/10.3390/cancers13174346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8431634/
https://www.ncbi.nlm.nih.gov/pubmed/34503156
http://dx.doi.org/10.3390/cancers13174346

Ejemplares similares